Sun Pharma falls after BofA downgrade; key supports in focus
Sun Pharmaceutical Industries slid 3.4% to ₹1,601 after BofA Securities cut its rating to underperform and slashed the target to ₹1,570 from ₹1,730,citing stretched valuations and weak traction in its specialty drug portfolio. Analyst flagged support at ₹1,528-1,552 and resistance at ₹1,696-1,766. Stocktwits sentiment turned bearish, with the stock down 15% YTD amid earnings and tariff pressures.